BioCardia director granted stock options for 12,000 shares
BioCardia, Inc. reported an insider equity award to one of its directors.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
BioCardia, Inc. reported an insider equity award to one of its directors. On 12/08/2025, the director received a stock option to purchase 12,000 shares of BioCardia common stock at an exercise price of $1.37 per share. The option vests and becomes fully exercisable on the one-year anniversary of the grant date, so long as the director continues as a service provider through that date, and it expires on 12/08/2035. Following this grant, the director beneficially owns 15,729 derivative securities, held directly.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 12,000 | $0.00 | $0.00 |
Footnotes (1)
- F1. One hundred percent of the shares are subject to the option vesting and becoming exercisable on the one-year anniversary of the date of grant, subject to the Reporting Person continuing as a service provider through such date.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did BioCardia (BCDA) report in this Form 4?
What is the exercise price of the BioCardia (BCDA) stock options granted?
When do the BioCardia (BCDA) director stock options vest and become exercisable?
When do the newly granted BioCardia (BCDA) stock options expire?
How many derivative securities does the BioCardia (BCDA) director own after this transaction?
What is the reporting person’s relationship to BioCardia (BCDA)?
AI-generated analysis. How Rhea-AI works. Not financial advice.